Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15
Verastem Is Maintained at Outperform by Mizuho
Verastem Analyst Ratings
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $8
Citi Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $10
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $10
Verastem Is Maintained at Buy by Guggenheim
Verastem Price Target Raised to $14.00/Share From $13.00 by Guggenheim
Verastem (VSTM) Gets a Buy From Mizuho Securities
HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $10
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $20
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14
Verastem Analyst Ratings
BTIG Sticks to Its Buy Rating for Verastem (VSTM)
Alliance Global Partners Remains a Buy on Verastem (VSTM)
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Verastem (VSTM)
B.Riley Financial Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $9
Verastem Analyst Ratings